menu
    • menu
    [{"orgOrder":0,"company":"Formosa Laboratories","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formosa Laboratories","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Formosa Laboratories \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Formosa Laboratories \/ Formosa Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Formosa Laboratories

    Menu

    Formosa Laboratories

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Formosa Laboratories

                            Taiwan arrow
                            Discovery on Target
                            Not Confirmed

                            Formosa Laboratories

                            Taiwan arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Sosei Heptares

                            Deal Size : $8.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

                            Details : First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they ...

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Sosei Heptares

                            Deal Size : $8.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth